Holmes Cheryl L, Landry Donald W, Granton John T
Department of Medicine, Division of Critical Care, Kelowna General Hospital, Kelowna BC, Canada.
Crit Care. 2004 Feb;8(1):15-23. doi: 10.1186/cc2338. Epub 2003 Jun 26.
Vasopressin is emerging as a rational therapy for vasodilatory shock states. In part 1 of the review we discussed the structure and function of the various vasopressin receptors. In part 2 we discuss vascular smooth muscle contraction pathways with an emphasis on the effects of vasopressin on ATP-sensitive K+ channels, nitric oxide pathways, and interaction with adrenergic agents. We explore the complex and contradictory studies of vasopressin on cardiac inotropy and coronary vascular tone. Finally, we summarize the clinical studies of vasopressin in shock states, which to date have been relatively small and have focused on physiologic outcomes. Because of potential adverse effects of vasopressin, clinical use of vasopressin in vasodilatory shock should await a randomized controlled trial of the effect of vasopressin's effect on outcomes such as organ failure and mortality.
血管加压素正逐渐成为治疗血管舒张性休克状态的合理疗法。在本综述的第1部分,我们讨论了各种血管加压素受体的结构和功能。在第2部分,我们讨论血管平滑肌收缩途径,重点是血管加压素对ATP敏感性钾通道、一氧化氮途径的影响以及与肾上腺素能药物的相互作用。我们探讨了血管加压素对心肌收缩力和冠状血管张力的复杂且相互矛盾的研究。最后,我们总结了血管加压素在休克状态下的临床研究,迄今为止这些研究规模相对较小,且主要关注生理结果。由于血管加压素存在潜在不良反应,血管加压素在血管舒张性休克中的临床应用应等待一项关于血管加压素对器官衰竭和死亡率等结局影响的随机对照试验。